source
- Merck's sac-TMT shows promise in Chinese Phase 3 lung cancer trial, may replace chemoMerck and its Chinese partner Kelun-Biotech reported that the antibody-drug conjugate sac-TMT slowed disease progression better than a standard chemotherapy regimen in a Phase 3 trial conducted in…
- Celcuity’s breast cancer therapy gets FDA approval as new CBER chief outlines biotech prioritiesCelcuity announced that its first breast cancer drug has been approved by the U.S. Food and Drug Administration, marking the company’s initial market entry in oncology. The announcement coincided…